세계의 파괴적 행동 장애(DBD) 치료 시장 기회, 성장 촉진요인, 산업 동향 분석 및 예측(2025-2034년)

The Global Disruptive Behavior Disorder Treatment Market generated USD 1.5 billion in 2024 and is projected to grow at a CAGR of 5.4% between 2025 and 2034. This market addresses conditions such as oppositional defiant disorder (ODD), intermittent explosive disorder (IED), and conduct disorder (CD), which primarily affect children and adolescents. The rising prevalence of these disorders, coupled with an increasing focus on mental health awareness, is driving the demand for effective treatment options. As parents, educators, and healthcare providers recognize the importance of early intervention, the need for specialized care is growing.

Moreover, advancements in treatment modalities, including behavioral therapies and pharmacological interventions, are offering more comprehensive solutions for managing these disorders. Government initiatives aimed at improving mental health services and increasing access to treatment are further boosting market growth. The growing emphasis on evidence-based therapies, coupled with an increasing number of clinical studies to evaluate the effectiveness of new treatments, is expected to contribute significantly to the market's expansion. Additionally, the integration of digital health technologies and teletherapy services is making treatment more accessible to a wider demographic, driving further growth in the coming years.

The market is segmented into three primary disorder types: conduct disorder, intermittent explosive disorder, and oppositional defiant disorder. Conduct disorder accounted for the largest share of the market, generating USD 1 billion in 2024. This dominance is attributed to the high prevalence of the disorder among children and adolescents, characterized by persistent patterns of aggressive, disruptive, and antisocial behaviors. These behaviors often necessitate intensive treatment involving both pharmacological interventions, such as antipsychotic medications, and behavioral therapies. The increasing need for personalized and multi-faceted treatment options has fueled the steady growth of this segment.

Treatment options for disruptive behavior disorders include both medications and therapy, with the therapy segment dominating the market. Therapy accounted for 59.4% of the market share in 2024 and is expected to generate USD 1.5 billion by 2034. Therapy options are extensive and include family therapy, cognitive-behavioral therapy (CBT), and social-emotional skills training, all of which play a crucial role in addressing emotional regulation and improving family dynamics. Therapy remains the most widely utilized treatment approach, with mental health professionals tailoring interventions to meet the specific needs of affected individuals. Pharmacological treatments, including antipsychotics and ADHD medications, continue to serve as valuable adjuncts, particularly in cases where behavioral interventions alone are insufficient.

The U.S. disruptive behavior disorder treatment market generated USD 580.7 million in 2023, driven by a growing number of diagnosed individuals and the country's ongoing investment in healthcare innovations. As the focus on mental health intensifies, the development of more effective therapies is contributing to sustained market growth. Increased funding for mental health programs, coupled with a rise in research initiatives, is fostering the advancement of treatment options, ensuring continuous improvements in care delivery across the country.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates and calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Rising prevalence of behavioral disorders
    • 3.2.1.2 Integration of digital therapeutics
    • 3.2.1.3 Increasing awareness and early diagnosis
    • 3.2.1.4 Evolving government policies and support
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 Social stigma associated with mental health disorders
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Future market trends
• 3.6 Gap analysis
• 3.7 Porter's analysis
• 3.8 PESTEL analysis

Chapter 4 Competitive Landscape, 2024

• 4.1 Introduction
• 4.2 Company market share analysis
• 4.3 Company matrix analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Disorder Type, 2021 – 2034 ($ Mn)

• 5.1 Key trends
• 5.2 Oppositional defiant disorder
• 5.3 Conduct disorder
• 5.4 Intermittent explosive disorder

Chapter 6 Market Estimates and Forecast, By Treatment Type, 2021 – 2034 ($ Mn)

• 6.1 Key trends
• 6.2 Drugs
  • 6.2.1 Antipsychotics
  • 6.2.2 Stimulants
  • 6.2.3 Non-stimulant ADHD medications
  • 6.2.4 Other drugs
• 6.3 Therapy
  • 6.3.1 Comprehensive evaluation
  • 6.3.2 Family therapy
  • 6.3.3 Parenting modification
  • 6.3.4 Group therapy
  • 6.3.5 Individual therapy
  • 6.3.6 Social and emotional skills training

Chapter 7 Market Estimates and Forecast, By End Use, 2021 – 2034 ($ Mn)

• 7.1 Key trends
• 7.2 Hospitals
• 7.3 Psychiatric clinics
• 7.4 Rehabilitation centers
• 7.5 Other end use

Chapter 8 Market Estimates and Forecast, By Region, 2021 – 2034 ($ Mn)

• 8.1 Key trends
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 UK
  • 8.3.3 France
  • 8.3.4 Spain
  • 8.3.5 Italy
  • 8.3.6 Netherlands
• 8.4 Asia Pacific
  • 8.4.1 China
  • 8.4.2 India
  • 8.4.3 Japan
  • 8.4.4 Australia
  • 8.4.5 South Korea
• 8.5 Latin America
  • 8.5.1 Brazil
  • 8.5.2 Mexico
  • 8.5.3 Argentina
• 8.6 Middle East and Africa
  • 8.6.1 Saudi Arabia
  • 8.6.2 South Africa
  • 8.6.3 UAE

Chapter 9 Company Profiles

• 9.1 Drugs:
  • 9.1.1 Bionomics
  • 9.1.2 Eli Lilly and Company
  • 9.1.3 Johnson & Johnson
  • 9.1.4 Mylan
  • 9.1.5 Novartis
  • 9.1.6 Pfizer
  • 9.1.7 Takeda Pharmaceuticals
• 9.2 Therapy:
  • 9.2.1 Boston Children's Hospital
  • 9.2.2 Highland Ridge Hospital
  • 9.2.3 INTEGRIS Health
  • 9.2.4 Lakeview Health
  • 9.2.5 Springwoods Behavioral Health